By Clínica Geral USA · Licensed Doctors & Nurse Practitioners
GLP-1 medications have transformed weight management in the United States. With clinical trials showing 15-22% body weight reduction, Ozempic, Wegovy, Mounjaro, and Zepbound have become the most sought-after weight loss treatments — and for good reason.
GLP-1 (Glucagon-Like Peptide-1) receptor agonists mimic a natural gut hormone that regulates appetite and blood sugar. They work by:
| Medication | Active Ingredient | FDA Approved For | Avg Weight Loss |
|---|---|---|---|
| Ozempic® | Semaglutide 0.5-2mg | Type 2 Diabetes | ~14% |
| Wegovy® | Semaglutide 2.4mg | Obesity (BMI ≥30) | ~15-17% |
| Mounjaro® | Tirzepatide | Type 2 Diabetes | ~19% |
| Zepbound® | Tirzepatide | Obesity (BMI ≥30) | ~20-22% |
Clínica Geral USA provides GLP-1 programs with complete medical supervision in Portuguese, English, and Spanish across Florida, Colorado, Connecticut, and Arizona.
Complete evaluation of eligibility and medical history.
HbA1c, metabolic panel, thyroid, and other relevant tests.
Electronic prescription sent to your preferred pharmacy.
Dose adjustments and ongoing medical support.
Free 15-minute consultation. Bilingual care. All across the USA.
Book Free Consultation →